ImageneBio, Inc. SEC filings IMA
ImageneBio, Inc. has 336 filings in SEC EDGAR's recent list, going back to Jan 8, 2021. Its latest annual report, Form ARS, was filed on Apr 30, 2026 for the period ended Dec 31, 2025. The latest quarterly report (Form 10-Q) was filed on Aug 5, 2026, covering the quarter ended Jun 30, 2026. The most recent current report (Form 8-K) was filed on Aug 5, 2026 (results of operations). The company's fiscal year ends on December 31.
| Form | Description | Filed | Period |
|---|---|---|---|
| EFFECT | Filing | Aug 11, 2026 | — |
| EFFECT | Filing | Aug 11, 2026 | — |
| EFFECT | Filing | Aug 6, 2026 | — |
| S-8 | Employee stock plan registration | Aug 5, 2026 | — |
| S-3 | Shelf registration | Aug 5, 2026 | — |
| POS AM | Filing | Aug 5, 2026 | — |
| 424B3 | Prospectus | Aug 5, 2026 | — |
| S-3 | Shelf registration | Aug 5, 2026 | — |
| 10-Q | Quarterly report | Aug 5, 2026 | Jun 30, 2026 |
| 8-K |
Current report
Results of operations
|
Aug 5, 2026 | Aug 5, 2026 |
| 424B3 | Prospectus | Jul 23, 2026 | — |
| 8-K |
Current report
Officer or director change, Other events
|
Jul 23, 2026 | Jul 20, 2026 |
| 424B3 | Prospectus | Jun 29, 2026 | — |
| 8-K |
Current report
Officer or director change
|
Jun 26, 2026 | Jun 22, 2026 |
| 424B3 | Prospectus | Jun 17, 2026 | — |
| 8-K |
Current report
Officer or director change, Shareholder vote results
|
Jun 17, 2026 | Jun 16, 2026 |
| 424B3 | Prospectus | May 8, 2026 | — |
| 424B3 | Prospectus | May 7, 2026 | — |
| 10-Q | Quarterly report | May 7, 2026 | Mar 31, 2026 |
| 8-K |
Current report
Results of operations
|
May 7, 2026 | May 7, 2026 |
| ARS | Annual report to shareholders | Apr 30, 2026 | Dec 31, 2025 |
| DEFA14A | Additional proxy material | Apr 30, 2026 | — |
| DEF 14A | Proxy statement | Apr 30, 2026 | Jun 16, 2026 |
| 424B3 | Prospectus | Apr 13, 2026 | — |
| 8-K |
Current report
Material agreement, Unregistered share sale
|
Apr 13, 2026 | Apr 12, 2026 |
| EFFECT | Filing | Apr 3, 2026 | — |
| POS AM | Filing | Apr 2, 2026 | — |
| 8-K |
Current report
Officer or director change
|
Mar 17, 2026 | Mar 12, 2026 |
| S-8 | Employee stock plan registration | Mar 10, 2026 | — |
| 10-K | Annual report | Mar 10, 2026 | Dec 31, 2025 |
| 8-K |
Current report
Results of operations
|
Mar 10, 2026 | Mar 10, 2026 |
| 424B3 | Prospectus | Feb 17, 2026 | — |
| 8-K |
Current report
Officer or director change
|
Feb 17, 2026 | Feb 12, 2026 |
| 424B3 | Prospectus | Dec 18, 2025 | — |
| 8-K |
Current report
Officer or director change
|
Dec 18, 2025 | Dec 12, 2025 |
| 8-K |
Current report
Regulation FD disclosure
|
Nov 19, 2025 | Nov 19, 2025 |
| S-8 | Employee stock plan registration | Nov 12, 2025 | — |
| 424B3 | Prospectus | Nov 12, 2025 | — |
| 10-Q | Quarterly report | Nov 12, 2025 | Sep 30, 2025 |
| 8-K |
Current report
Results of operations
|
Nov 12, 2025 | Nov 12, 2025 |
| 424B3 | Prospectus | Nov 5, 2025 | — |
| 8-K |
Current report
Officer or director change
|
Nov 5, 2025 | Nov 1, 2025 |
| 424B3 | Prospectus | Oct 30, 2025 | — |
| 8-K |
Current report
Material agreement, Agreement ended
|
Oct 29, 2025 | Oct 23, 2025 |
| 8-K |
Current report
Officer or director change
|
Oct 22, 2025 | Oct 21, 2025 |
| 8-K |
Current report
Officer or director change
|
Oct 10, 2025 | Oct 10, 2025 |
| EFFECT | Filing | Sep 15, 2025 | — |
| CORRESP | Letter to the SEC | Sep 11, 2025 | — |
| UPLOAD | Letter from the SEC | Sep 11, 2025 | — |
| S-1 | Registration statement | Sep 8, 2025 | — |
| 8-K/A |
Amended current report
Acquisition or sale of assets
|
Aug 12, 2025 | Jul 25, 2025 |
| 8-K |
Current report
Auditor change
|
Aug 5, 2025 | Aug 2, 2025 |
| 8-K |
Current report
Officer or director change, Other events
|
Aug 1, 2025 | Jul 28, 2025 |
| 8-K |
Current report
Material agreement, Acquisition or sale of assets, Unregistered share sale, Change to shareholder rights, Change in control, Officer or director change, Bylaw or fiscal year change, Regulation FD disclosure
|
Jul 29, 2025 | Jul 25, 2025 |
| 8-K |
Current report
Regulation FD disclosure
|
Jul 25, 2025 | Jul 25, 2025 |
| 10-Q | Quarterly report | Jul 24, 2025 | Jun 30, 2025 |
| 8-K |
Current report
Other events
|
Jul 24, 2025 | Jul 24, 2025 |
| 8-K |
Current report
Other events
|
Jul 22, 2025 | Jul 22, 2025 |
| D | Filing | Jul 18, 2025 | — |
| 8-K |
Current report
Officer or director change
|
Jul 16, 2025 | Jul 15, 2025 |
| 8-K |
Current report
Officer or director change, Shareholder vote results, Other events
|
Jul 15, 2025 | Jul 15, 2025 |
| 425 | Filing | Jul 11, 2025 | — |
| 8-K |
Current report
Other events
|
Jul 11, 2025 | Jul 11, 2025 |
| 425 | Filing | Jul 1, 2025 | — |
| 8-K |
Current report
Regulation FD disclosure, Other events
|
Jul 1, 2025 | Jul 1, 2025 |
| EFFECT | Filing | Jun 11, 2025 | — |
| 424B3 | Prospectus | Jun 11, 2025 | — |
| CORRESP | Letter to the SEC | Jun 10, 2025 | — |
| S-4/A | Filing | Jun 9, 2025 | — |
| CORRESP | Letter to the SEC | Jun 9, 2025 | — |
| UPLOAD | Letter from the SEC | Jun 3, 2025 | — |
| S-4/A | Filing | May 30, 2025 | — |
| S-4/A | Filing | May 20, 2025 | — |
| 10-Q | Quarterly report | May 8, 2025 | Mar 31, 2025 |
| CORRESP | Letter to the SEC | May 7, 2025 | — |
| S-4/A | Filing | May 7, 2025 | — |
| UPLOAD | Letter from the SEC | May 2, 2025 | — |
| CORRESP | Letter to the SEC | Apr 21, 2025 | — |
| S-4/A | Filing | Apr 21, 2025 | — |
| UPLOAD | Letter from the SEC | Apr 14, 2025 | — |
| S-4 | Registration for a merger or exchange | Mar 18, 2025 | — |
| ARS | Annual report to shareholders | Mar 6, 2025 | Dec 31, 2024 |
| 10-K | Annual report | Mar 6, 2025 | Dec 31, 2024 |
| 425 | Filing | Jan 10, 2025 | — |
| 425 | Filing | Dec 23, 2024 | — |
| 8-K |
Current report
Material agreement, Unregistered share sale, Change in control, Officer or director change, Regulation FD disclosure
|
Dec 23, 2024 | Dec 23, 2024 |
| 10-Q | Quarterly report | Nov 7, 2024 | Sep 30, 2024 |
| 10-Q | Quarterly report | Aug 8, 2024 | Jun 30, 2024 |
| 8-K |
Current report
Officer or director change
|
Jul 12, 2024 | Jul 8, 2024 |
| 8-K |
Current report
Shareholder vote results
|
Jun 10, 2024 | Jun 7, 2024 |
| 8-K |
Current report
Exit or restructuring costs, Regulation FD disclosure, Other events
|
May 28, 2024 | May 23, 2024 |
| 10-Q | Quarterly report | May 13, 2024 | Mar 31, 2024 |
| ARS | Annual report to shareholders | Apr 26, 2024 | Dec 31, 2023 |
| DEFA14A | Additional proxy material | Apr 26, 2024 | — |
| DEF 14A | Proxy statement | Apr 26, 2024 | Jun 7, 2024 |
| S-8 | Employee stock plan registration | Mar 12, 2024 | — |
| 10-K | Annual report | Mar 12, 2024 | Dec 31, 2023 |
| 8-K |
Current report
Officer or director change, Regulation FD disclosure
|
Feb 21, 2024 | Feb 20, 2024 |
| 8-K |
Current report
Results of operations, Exit or restructuring costs, Regulation FD disclosure, Other events
|
Jan 18, 2024 | Jan 17, 2024 |
| 10-Q | Quarterly report | Nov 9, 2023 | Sep 30, 2023 |
| 8-K |
Current report
Results of operations, Other events
|
Nov 9, 2023 | Nov 9, 2023 |
| 8-K |
Current report
Shareholder vote results
|
Oct 11, 2023 | Oct 11, 2023 |
| DEF 14A | Proxy statement | Sep 25, 2023 | Oct 11, 2023 |
| PRE 14A | Preliminary proxy statement | Sep 15, 2023 | Sep 15, 2023 |
| 424B5 | Prospectus supplement | Sep 12, 2023 | — |
| EFFECT | Filing | Sep 8, 2023 | — |
| CORRESP | Letter to the SEC | Sep 6, 2023 | — |
| D | Filing | Aug 18, 2023 | — |
| S-3 | Shelf registration | Aug 18, 2023 | — |
| 10-Q | Quarterly report | Aug 10, 2023 | Jun 30, 2023 |
| 8-K |
Current report
Material agreement, Acquisition or sale of assets, Unregistered share sale, Bylaw or fiscal year change, Regulation FD disclosure
|
Aug 7, 2023 | Aug 4, 2023 |
| 8-K |
Current report
Listing notice
|
Jun 30, 2023 | Jun 30, 2023 |
| 8-K |
Current report
Shareholder vote results
|
Jun 9, 2023 | Jun 9, 2023 |
| 8-K |
Current report
Material agreement, Regulation FD disclosure, Other events
|
May 15, 2023 | May 15, 2023 |
| 424B5 | Prospectus supplement | May 15, 2023 | — |
| 10-Q | Quarterly report | May 15, 2023 | Mar 31, 2023 |
| ARS | Annual report to shareholders | Apr 28, 2023 | Dec 31, 2022 |
| DEFA14A | Additional proxy material | Apr 28, 2023 | — |
| DEF 14A | Proxy statement | Apr 28, 2023 | Jun 9, 2023 |
| 8-K |
Current report
Regulation FD disclosure, Other events
|
Apr 17, 2023 | Apr 17, 2023 |
| S-8 | Employee stock plan registration | Mar 14, 2023 | — |
| 10-K | Annual report | Mar 14, 2023 | Dec 31, 2022 |
| 8-K |
Current report
Officer or director change
|
Dec 19, 2022 | Dec 14, 2022 |
| 8-K |
Current report
Regulation FD disclosure, Other events
|
Nov 28, 2022 | Nov 28, 2022 |
| 8-K |
Current report
Regulation FD disclosure, Other events
|
Nov 10, 2022 | Nov 10, 2022 |
| 10-Q | Quarterly report | Nov 7, 2022 | Sep 30, 2022 |
| 10-Q | Quarterly report | Aug 11, 2022 | Jun 30, 2022 |
| 8-K |
Current report
Shareholder vote results
|
Jun 10, 2022 | Jun 9, 2022 |
| 10-Q | Quarterly report | May 12, 2022 | Mar 31, 2022 |
| EFFECT | Filing | May 5, 2022 | — |
| CORRESP | Letter to the SEC | May 3, 2022 | — |
| UPLOAD | Letter from the SEC | May 2, 2022 | — |
| S-3 | Shelf registration | Apr 27, 2022 | — |
| DEFA14A | Additional proxy material | Apr 27, 2022 | — |
| DEF 14A | Proxy statement | Apr 27, 2022 | Jun 9, 2022 |
| 8-K |
Current report
Officer or director change
|
Apr 13, 2022 | Apr 13, 2022 |
| 8-K |
Current report
Other events
|
Apr 6, 2022 | Apr 6, 2022 |
| S-8 | Employee stock plan registration | Mar 17, 2022 | — |
| 10-K | Annual report | Mar 17, 2022 | Dec 31, 2021 |
| 8-K |
Current report
Officer or director change
|
Feb 24, 2022 | Feb 18, 2022 |
| 8-K |
Current report
Officer or director change
|
Jan 28, 2022 | Jan 28, 2022 |
| 8-K |
Current report
Officer or director change
|
Jan 26, 2022 | Jan 21, 2022 |
| 8-K |
Current report
Regulation FD disclosure
|
Nov 10, 2021 | Nov 10, 2021 |
| 10-Q | Quarterly report | Nov 10, 2021 | Sep 30, 2021 |
| 10-Q | Quarterly report | Aug 12, 2021 | Jun 30, 2021 |
| 8-K |
Current report
Results of operations
|
Aug 12, 2021 | Aug 12, 2021 |
| 10-Q | Quarterly report | May 13, 2021 | Mar 31, 2021 |
| 8-K |
Current report
Results of operations
|
May 13, 2021 | May 13, 2021 |
| 8-K |
Current report
Officer or director change
|
Apr 15, 2021 | Apr 15, 2021 |
| 8-K |
Current report
Officer or director change, Bylaw or fiscal year change
|
Mar 30, 2021 | Mar 25, 2021 |
| S-8 | Employee stock plan registration | Mar 30, 2021 | — |
| 424B4 | Prospectus | Mar 26, 2021 | — |
| EFFECT | Filing | Mar 25, 2021 | — |
| SEC STAFF LETTER | Filing | Mar 25, 2021 | — |
| CERT | Filing | Mar 25, 2021 | — |
| 8-A12B | Filing | Mar 23, 2021 | — |
| CORRESP | Letter to the SEC | Mar 23, 2021 | — |
| CORRESP | Letter to the SEC | Mar 23, 2021 | — |
| S-1/A | Amended registration statement | Mar 22, 2021 | — |
| CORRESP | Letter to the SEC | Mar 12, 2021 | — |
| CORRESP | Letter to the SEC | Mar 5, 2021 | — |
| S-1 | Registration statement | Mar 5, 2021 | — |
| SEC STAFF LETTER | Filing | Mar 1, 2021 | — |
| UPLOAD | Letter from the SEC | Feb 25, 2021 | — |
| DRSLTR | Filing | Feb 11, 2021 | — |
| DRS/A | Filing | Feb 11, 2021 | — |
| UPLOAD | Letter from the SEC | Feb 8, 2021 | — |
| DRS | Filing | Jan 8, 2021 | — |
Showing 168 filings. Main filings leave out insider and ownership forms such as Form 4; choose a type above to see them. Each form opens on SEC.gov. Older filings are on SEC EDGAR.
New to this? Read What Are SEC Filings? 10-K, 10-Q, 8-K and Other Forms Explained.
Company profile
- Industry
- Biological Products, (No Diagnostic Substances) (SIC 2836)
- Listed as
- IMA (Nasdaq)
- Fiscal year ends
- December 31
- Incorporated in
- DE
- Headquarters
- San Diego, CA
- SEC filer status
- Non-accelerated filer, Smaller reporting company, Emerging growth company
- SEC CIK
- 1835579
- Former names
- Ikena Oncology, Inc. (until Jul 25, 2025)
Other Biological Products, (No Diagnostic Substances) companies
- Amgen Inc AMGN
- Gilead Sciences, Inc. GILD
- Moderna, Inc. MRNA
- Argenx SE ARGX
- Revolution Medicines, Inc. RVMD
- Biogen Inc. BIIB
- BioNTech SE BNTX
- Exelixis, Inc. EXEL
All 182 Biological Products, (No Diagnostic Substances) companies
Source: SEC EDGAR filings. This is company-reported data, not investment advice.